A key ambition of BenevolentAI is to use artificial intelligence to revolutionize the drug development process. Now, with a licensing agreement with Janssen, it is one significant step closer to realizing that dream.
Advertisements
BenevolentAI uses cognitive computing, semantic search to speed development of in-licensed drugs
